| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Unité de Recombinaison et Expression Génétique, Institut National de la Santé et de la Recherche Médicale, Unité 163, Institut Pasteur, Paris, France;
IDM, Immuno-Designed Molecules, Paris, France; and
Unité d’Immunité Cellulaire Antivirale, Institut Pasteur, Paris, France
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
-secreting CD8+ T
lymphocytes specific for endogenously processed peptides and with
recognition specificities similar to those described during
self-limited infection in humans. This suggests that responses induced
by DNA immunization could have the same immune potential as those
developing during natural HBV infection in human
patients. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
, IFN-
, IFN-ß, and TNF-) secreted by
CD8+ T cells after antigenic stimulation or
following a concomitant viral infection (8).
At present, there is no efficient cure for HBV chronic infections.
IFN- treatment is efficient in only 40% of patients, and treatment
with nucleoside analogues leads to the development of drug resistance
in some patients. Specific immunotherapies such as injection of
envelope based-recombinant vaccine (9) or core-specific
lipopeptides (10, 11) have been designed to induce or to
boost cellular responses in chronically infected patients.
DNA-based immunization represents a promising approach to induce specific cytotoxic responses. It is achieved by intradermal or i.m. injection of DNA plasmids encoding one or several Ags. The in vivo production of the Ag leads to a complete immune response, with production of Abs and the initiation of long-lasting CD4+- and CD8+-specific T cell responses (12). We have developed DNA immunization against HBV based on injection of vectors encoding hepatitis B surface Ag (HBsAg) (13, 14). To date, several constructs have been tested in different animal models (mice and nonhuman primates) in which Abs (15, 16), CD4+ T cell proliferative responses (17), and CD8+ CTL were induced (18, 19, 20). Results obtained in HBsAg-transgenic mice, an animal model for HBV chronic carriers, suggested that DNA-based immunization against HBsAg could induce or increase the immune response in chronically infected patients (6, 17). These results have been further confirmed in duck and woodchuck as animal models for hepadnavirus infection (21, 22).
Before applying genetic immunization approaches to humans, we sought to verify that injection of a plasmid encoding an Ag allows the generation of cytotoxic T cells of specificities comparable to those observed in infected patients. To address this question, we studied the specificity of cytotoxic responses induced in HLA-A*0201 transgenic mice (23) by DNA immunization with regard to that observed during acute infection in humans (3, 24). In this study we have analyzed the cytotoxic responses against previously defined HLA-A*0201-restricted epitopes of HBsAg after a single injection of a plasmid encoding the small and the middle HBV envelope proteins, both carrying the HBsAg. This was performed in Human Human Db (HHD) mice derived from a strain deficient for the ß2-microglobulin (ß2m) gene and the mouse MHC class-I H-2Db molecules and transgenic for a chimeric HLA-A*0201/Db molecule. In these animals the chimeric molecule is the only class I molecule serologically detected on cell surfaces (23). After infection or immunization, these mice have been shown to be a relevant animal model for HLA-A*0201-restricted epitope presentation (25, 26).
Our results demonstrate that the CD8+ T cell response induced by injection of plasmids encoding the HBV envelope proteins in HHD mice is multiepitopic and that its specificity mimics the responses of HBV-infected patients.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Female HHD+/+
ß2m-/-
Db-/- mice used for immunization were 6–8 wk
old. The ß2m-/-
Db-/- strain was made transgenic for a chimeric
HLA-A*0201 monochain, the HHD molecule (23) in which
the human ß2m molecule is covalently linked to
the NH2 terminus of a hybrid MHC class I heavy
chain. The hybrid heavy chain is composed of the 1 and 2 domains
of the human HLA-A*0201 MHC class I molecule and the 3,
transmembrane, and cytoplasmic domains of the mouse
H-2Db MHC class I molecule. The expression of
this monomeric MHC class I molecule on the cell surfaces in
ß2m- and H-2Db-deficient
mice restores a partial CD8+ population in the
spleen that represents 5% of total splenocytes.
Peptides and immunization
Peptides synthesized by Neosystem (Strasbourg, France) were dissolved in PBS-10% DMSO at a concentration of 2 mg/ml. Groups of five to nine mice were immunized once with 50 µg of HLA-A*0201-restricted peptide combined with 140 µg of T helper peptide (hepatitis B nucleocapside, HBc128–140 TPPATRPPNAPIL) emulsified in IFA (Difco, Detroit, MI). The emulsion (100 µl) was injected s.c. at the base of the tail (27). For loading LPS blasts and target cells, peptides were dissolved in RPMI-20% DMSO at 1 mg/ml, aliquoted, and stored at -20°C.
Peptide binding and stabilization of HLA-A*0201 molecules
T2 cells (TAP-, HLA-A*0201+) were incubated overnight at 37°C in serum-free RPMI medium supplemented with 100 ng/ml human ß2m (Sigma, St. Louis, MO) in the absence or the presence of HLA-A*0201-tested peptides at various final concentrations (10, 1, and 0.1 µM). Subsequently, the level of HLA-A*0201 molecules stabilized in the presence of a given peptide was evaluated by FACS analysis. Briefly, T2 cells were incubated for 20 min at 4°C with an anti-HLA-A*0201 mAb (BB7.2), washed twice, incubated with FITC-conjugated anti-mouse IgG (Diagnostic Pasteur, Marnes la Coquette, France), washed twice, incubated in PBS containing 1/1000 propidium iodide, and analyzed using a FACSCalibur cytofluorometer (Becton Dickinson, San Jose, CA). The mean intensity of fluorescence observed for each peptide concentration after subtraction of the mean intensity of fluorescence observed without peptide was used as an estimate of peptide binding. A peptide derived from the hepatitis B nucleocapside HBc18–27 (FLPSFFPSV) was used as a positive control to define the maximal binding (27). For each peptide, the concentration needed to reach 20% of maximal binding was calculated. RA is the ratio of the concentration of tested peptide and that of HBc18–27 reference peptide needed to reach this value (25).
HBsAg expression vector and DNA-based immunization
The pCMV-S2.S plasmid contains part of the envelope-coding domain of the HBV genome. In this plasmid (14) the pre-S2 and S HBV domains were placed under transcriptional control of the human CMV immediate early gene promoter, allowing the expression of the HBV small and the middle envelope proteins, both carrying the HBsAg. Plasmid DNA used for in vivo immunization was prepared using Qiagen DNA purification columns (Endofree Plasmid Kit; Qiagen, Hilden, Germany). For DNA-based immunization, HBsAg expression vector pCMV-S2.S was injected directly into regenerating tibialis anterior muscles as previously described (13, 28). Each muscle was injected with 50 µl of DNA at 1 mg/ml in PBS, such that each animal received a total of 100 µg of DNA. All i.m. injections were conducted under anesthesia (sodium pentobarbital, 75 mg/kg i.p.). All experiments involving mice were conducted in accordance with institutional guidelines.
Cell lines
All cell lines were cultured in RPMI 1640 medium (Life Technologies, Cergy-Pontoise, France) supplemented with 10% FCS, 100 µg/ml streptomycin, 100 IU/ml penicillin, and 2 mM L-glutamine (CM). HeLa and RMA-S cells were transfected with the HHD encoding construct as previously described (23), and P815 cells were transfected with the native HLA-A*0201 and human ß2m genes. Cell surface expression of the HHD monochain or the HLA-A*0201 molecule was verified by indirect immunofluorescence using mAb BB7.2 and anti-mouse IgG (Diagnostic Pasteur) and was monitored by FACS analysis. The LPS blast cells were obtained after red cell depletion by culturing splenocytes of nonimmunized syngeneic mice in CM supplemented with 5 x 10-5 M 2-ME, 1 mM sodium pyruvate, LPS from Salmonella typhosis (25 µg/ml; Sigma, St. Louis, MO), and dextran sulfate (7 µg/ml; Pharmacia, Uppsala, Sweden). After 3 days of culture, splenocytes were enriched with mature B cells. The cells were washed with serum-free medium and incubated for 3 h with the different HLA-A*0201 peptides (10 µg/ml) at room temperature. The LPS blasts were irradiated (40,000 rad) before coculture with splenocytes from immunized mice.
Measurement of CTL activity
Spleens were removed 7 or 8 days after peptide immunization or 3
wk after DNA immunization. RBC-depleted splenocytes (0.83%
NH4Cl, 5 min, on ice) were cultured (5 x
106 cells in 24-well plates) in -MEM (Life
Technologies) supplemented with 10 mM HEPES, nonessential amino acids,
1 mM sodium pyruvate, 5 x 10-5 M 2-ME,
antibiotics, and 10% FCS (Myoclone, Life Technologies). These cells
were stimulated for 6–7 days with peptide-loaded LPS-blast cells as
APCs at an effector-presenting cell ratio of 2:1 to 1:1. The specific
cytolytic activity of effector cells was tested in a short term
51Cr release assay against either RMA-S HHD or
HeLa HHD target cells pulsed with 10 µg/ml of the various HLA-A*0201
peptides derived from the HBV small envelope protein or target cells
pulsed with the well-described HLA-A*0201 HBV core epitope
(HBc18–27) as a negative control. After a 4-h
incubation at 37°C, supernatants were collected and counted on a beta
counter. Spontaneous and maximum releases were determined from wells
containing either medium alone or lysis buffer (5% Triton and 1%
SDS). Specific lysis was calculated in triplicate as
[(experimental - spontaneous release)/(maximum -
spontaneous release)] x 100. For some experiments secondary in vitro
restimulations were performed for an additional week as described
above, except that 5% T cell growth factor was added.
IFN- enzyme-linked immunospot (ELISPOT) assay
IFN--releasing cells were quantified after peptide- or
vaccinia virus-infected cell stimulation by cytokine-specific ELISPOT
assay. Ninety-six-well nitrocellulose-backed plates (Multiscreen;
Millipore, Molsheim, France) were coated with 50 µl of mouse IFN-
mAb (5 µg/ml; PharMingen, San Diego, CA) overnight at 4°C, then
washed three times with serum-free medium and blocked for 2 h
using CM. After red cell lysis, freshly isolated undepleted or
CD8+-depleted splenocytes (1 x
106/well) were incubated for 40 h in
complete -MEM medium (see CTL activity) at 37°C in 5%
CO2 using different antigenic stimulations. Cells
were incubated with either HLA-A*201-restricted peptide (1 µg/ml; see
Table I
) or a mouse MHC class
II-restricted peptide (HBs126–138) derived from
the pre-S2 domain of the HBV envelope middle protein (3 µg/ml)
(17) or were infected with a recombinant vaccinia virus
encoding the three HBV envelope proteins (rVV S1.S2.S)
(29) at a multiplicity of infection (MOI) of 1/1
(30). Quadruplicate determinations were made for
Ag-stimulated splenocytes, and triplicate determinations were made for
unstimulated splenocytes or for splenocytes infected with wild-type
vaccinia virus to determine background. Positive controls were made by
adding Con A (5 µg/ml) to the splenocytes. After incubation, cells
were lysed with water for 4 min, and the wells were washed three times
each with PBS-Tween or PBS alone before adding secondary
biotin-conjugated Ab (biotinylated anti-murine IFN-, PharMingen)
for 90 min at room temperature. The wells were washed as described
above before incubation with alkaline phosphatase-conjugated
streptavidin (Roche, Mannheim, Germany) at a 1/1000 dilution in PBS for
1.5 h. After rewashing as before, spots were developed by adding
peroxidase substrates, 5-bromo-4,3-indolyl phosphate and nitroblue
tetrazolium (Promega, Madison, WI). After the appearance of spots (30
min to 1 h) the reaction was stopped with tap water and air-dried.
Spots were counted in a double-blinded fashion as single spot-forming
cells (SFC) under a stereo binocular. The number of Ag-specific
IFN--secreting CD8+ T cells was determined by
subtracting the number of background spots from the number of spots
obtained for splenocytes stimulated with peptide or infected with
rVV-S1.S2.S. The percentage of CD8+ T cells was
determined by FACS analysis of fresh splenocytes using an
anti-mouse CD8+ FITC Ab (PharMingen).
Depletion of CD8+ T cells from mouse splenocytes
was achieved by magnetic cell sorting (MACS; Miltenyi Biotec, Paris,
France) as previously described (17). The percentage of
CD8+ T cells in the depleted fraction was
<0.4%.
|
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We have analyzed the capacity of eight HBV-envelope HLA-A*0201
peptides described as epitopes in humans to bind and stabilize the
HLA-A*0201 molecule on the T2 cell surface. T2 cells are HLA-A*0201
positive and TAP-negative human cells expressing unstable
HLA-A*0201 molecules at 37°C. Providing exogenous peptides
susceptible to bind HLA-A*0201 molecules results in their
stabilization. Cells were incubated overnight with peptide at various
concentrations, and the number of stabilized HLA-A*0201 molecules on
cell surface was quantified by FACS analysis. This test allowed us
to calculate the relative affinity for the HLA-A*0201 molecule of
each tested peptide after comparison with a reference peptide
(HBc18–27) displaying a high affinity
(27). The relative affinity for all peptides given in
Table I
was the mean of two individual experiments. These results
allowed us to distinguish peptides with high
(HBs260–269, HBs335–343,
HBs348–357), intermediate
(HBs183–191, HBs204–212,
HBs370–379), and very low
(HBs177–185 and
HBs251–259) affinities.
T cells from HHD mice recognize the HBV envelope HLA-A*0201-restricted epitopes
To evaluate whether the T cell repertoire of the HHD transgenic
mice is wide enough to recognize all HLA-A*0201-restricted epitopes
described previously in HBV-infected humans, mice were immunized
separately with the eight peptides corresponding to HLA-A*0201 epitopes
of the small HBV envelope protein (see Table I). To optimize the
cytotoxic responses, we coinjected the HLA-A*0201-restricted peptides
with a T helper peptide in IFA. After one s.c. peptide injection and
one in vitro peptide restimulation, we detected specific cytotoxicity
against all peptides tested (Fig. 1),
indicating that the eight HBV epitopes were efficiently presented by
the chimeric HHD molecule and that the HHD/epitope complex was well
recognized by TCR. Most peptides (HBs177–185,
HBs183–191, HBs204–212,
HBs260–269, HBs348–357,
and HBs370–379) induced a strong cytotoxic
response in almost all immunized mice, whereas two peptides
(HBs251–259 and
HBs335–343) induced a weaker response in some
injected mice. However, the weak response induced by injection of the
peptide HBs251–259 could be related to its very
low affinity for HLA-A*0201 molecule (Table I), which is probably
linked to peptide dimerization by cysteine (31). It is
surprising that the peptide HBs335–343, which
belongs to the high affinity group (Table I), did not induce a strong
CTL activity. Thus, no absolute correlation was found between the
HLA-A*0201 binding capacity and the frequency or intensity of the CTL
response. Nevertheless, cytotoxic activity could be elicited against
each tested peptide, indicating that despite the low number of
CD8+ T cells, the HLA-A*0201-educated repertoire
of HHD mice is wide enough to allow recognition of all envelope-derived
epitopes that have been described in HBV-infected human.
|
The pCMV-S2.S plasmid DNA was injected into regenerating muscle, a
condition previously found to be optimal for the induction of CTL
responses (20). Spleens were harvested 3 wk after
DNA-based immunization, and splenocytes were stimulated in vitro with
LPS blasts loaded with the different peptides to optimize peptide
presentation. Fig. 2 summarizes data from
CTL responses generated by DNA-based immunization and following a
single in vitro peptide stimulation. As observed with individual
peptide immunization, DNA injection generated cytotoxic responses
specific for all HLA-A2 epitopes tested. Different peptide response
profiles were observed. Responses specific for two epitopes
(HBs183–191 and
HBs348–357) were simultaneously induced in all
DNA-immunized mice (19 and 12 animals tested, respectively). Peptide
HBs370–379 had an intermediate pattern of
recognition, as 5 of 10 animals tested developed a specific cytotoxic
response. Responses specific for the other epitopes
(HBs177–185, HBs204–212,
HBs251–259, HBs260–269,
and HBs335–343) were sporadic. Interestingly,
peptides HBs251–259 and
HBs335–343 were also poorly immunogenic after
peptide immunization. Thus, following DNA-based immunization,
processing of the HBV envelope protein leads to an immunohierarchy in
CD8+ T cell responses, in which two superdominant
epitopes can be defined (HBs183–191 and
HBs348–357).
|
To assay the individual CTL responses to the eight
HLA-A2-restricted epitopes, the number of effector cells available
after a single in vitro stimulation was not always sufficient. Thus, we
performed secondary in vitro restimulation using all peptides
separately. As shown in Fig. 3 for four
animals, in each mouse we detected cytotoxic responses against the two
superdominant epitopes (HBs183–191 and
HBs348–357) that was also observed after a
single in vitro stimulation. Moreover, we detected simultaneous
responses against three to six epitopes per mouse, although the pattern
of peptide recognition varied from one animal to another. After two in
vitro stimulations cytotoxic responses were detected more frequently
and with increased cytolytic activity against the weaker epitopes, such
as peptides HBs177–185 and
HBs204–212 (Fig. 3A),
HBs370–379 (Fig. 3, A, B,
and D) and HBs260–269 (Fig. 3C). These results confirmed the significance of responses
against weak epitopes that were obtained at low frequency following 1
wk of in vitro stimulation. Moreover, we never observed in vitro CTL
induction from mice either unimmunized or immunized with an irrelevant
vector (pCMV-lacZ; data not shown). Thus, responses
generated against the superdominant epitopes do not inhibit responses
against weaker epitopes.
|
-secreting CD8+ T cells after
DNA-based immunization
To evaluate the frequency of HBV-specific
CD8+ T cells present in the spleen after
DNA-based immunization, we performed anti-IFN- ELISPOT assays 3
wk after immunization. The number of epitope-specific
CD8+ T cells was evaluated by measuring the
number of IFN--secreting cells in response to a short term
stimulation of splenocytes with the eight epitopic peptides tested
separately. The high frequency of T cells specific for peptide
HBs348–357 and peptide
HBs183–191 was found in all animals tested, and
T cells specific for peptide HBs370–379 were
found in 2 of 10 mice tested (Fig. 4).
The mean of CD8+ T cells specific for peptide
HBs348–357 was 2-fold higher than that for
peptide HBs183–191 (2/1000 and 1/1000 of total
CD8+ T cells, respectively). The number of T
cells specific for peptide HBs370–379 was 0.15
and 0.5/1000 CD8+ for two responder mice.
Interestingly, IFN--secreting T cells detected by the ELISPOT assay
were mainly specific for the two peptides described as superdominant in
the CTL assay after in vitro stimulation (see Figs. 2 and 3), but not
for the weak CTL epitopes. In addition, we never detected any
IFN--secreting T cells for an irrelevant control peptide
(HBc18–27). Detection of cytotoxic activity was
performed 1 wk after in vitro stimulation in the presence of
peptide-pulsed LPS blasts as APCs, a condition that favors the
amplification of CD8+ T cells by up to 10-fold,
as tested by FACS analysis (data not shown). In contrast, the ELISPOT
assay was performed ex vivo following short term restimulation. In
similar experimental conditions it has been shown that only a fraction
of perforin-positive T cells produce IFN- (32). Thus,
the precursor frequency of the CD8+ T cells
specific for the weak epitopes was probably too low to be detected in
this short term stimulation assay.
|
To fully characterize the cytotoxic response generated after
DNA-based immunization, we evaluated the cytotoxic activity of effector
cells toward target cells expressing the chimeric or the native
HLA-A*0201 molecule. We used effector cells specific for the two most
frequently recognized epitopes (HBs183–191 and
HBs348–357) derived from mice after a single DNA
injection and a single in vitro peptide stimulation. HHD-transfected
HeLa cells were used as targets to determine the level of lysis against
cells presenting the epitope bound to the chimeric HHD monochain
molecule. This was compared with the lysis mediated by the same
effector cells against the HLA-A*0201-transfected P815 targets that
present peptide associated with a human heterodimeric HLA-A*0201
molecule. Target cells presenting peptides on chimeric or on native HLA
molecules were lysed with comparable efficiency by the effector cells
(Fig. 5). This indicates that the
effector cells generated in HHD mice were able to recognize epitopes in
the native human HLA-A*0201 context, confirming that HHD mice are a
relevant animal model for studying HLA-A*0201-restricted responses.
Since murine CD8 molecules do not bind the 3 domain of human MHC
class I molecules, this suggests that effector cells specific for
peptide HBs183–191 and peptide
HBs347–358 generated after DNA-based
immunization do not require CD8 involvement for a functional
recognition between TCR and the peptide/MHC complex (Fig. 5, right).
|
Genetic immunization in HHD mice was shown to induce
HLA-A2-restricted CTL responses specific for previously described HBV
epitopes using peptides directly loaded onto target cells. To further
characterize this response we performed an ELISPOT assay to monitor the
T cell response to endogenously processed Ag. Splenocytes were infected
with recombinant vaccinia virus encoding the three HBV envelope
proteins carrying the HBsAg (rVV-S1.S2.S). The use of recombinant
vaccinia virus expressing the large envelope protein leads to cellular
accumulation of HBsAg without secretion of HBsAg particles
(33). Hence, this system avoids presentation of secreted
HBsAg to CD4+ T cells by APC. As shown in Fig. 6A, splenocytes from
DNA-immunized mice secrete IFN- in response to stimulation with
rVV-S1.S2.S-infected cells presenting endogenously processed HBV
peptides. The secretion of IFN- was not due to vaccinia virus
infection alone, as the background level of splenocytes infected with
wild-type vaccinia virus never exceeded 15
SFC/106 cells. To determine which cell type is
involved in IFN- secretion we simultaneously performed an ELISPOT
assay with CD8+ T cell-depleted splenocytes. The
number of SFC specific for rVV-S1.S2.S-infected cells was dramatically
decreased in the CD8+ T-depleted population (Fig. 6A), indicating that secretion of IFN- was due to
recognition of the epitope/HLA-A2 complex by CD8+
T cells only. As a control for cell functionality after magnetic
depletion, an ELISPOT assay using a pre-S2-specific T helper peptide
was performed (Fig. 6B). The number of IFN--secreting
CD4+ T cells did not differ before and after
CD8+ T cell depletion. These results show that
CD8+ T cells induced after pCMV-S2.S immunization
recognize HLA-A2-restricted epitopes derived from the processing of
endogenously produced HBV envelope proteins.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
following antigenic stimulation and recognize eight
epitopes that have been previously described in HBV-infected humans
during either the acute or the resolution phase of the disease. Genetic immunization is a powerful tool for the induction of strong cytotoxic responses in different animal models. However, cellular immune responses have usually been characterized in mice by examining a single immunodominant CTL epitope (18, 34). In the model of influenza, it has been shown that DNA-based immunization could lead to cytotoxic responses against subdominant epitopes only when the dominant epitope was mutated (35). Few studies have reported multispecific CTL responses, but these were performed using polyepitopic DNA vaccines (25, 36, 37) rather than plasmid encoding a full-length antigenic protein (38, 39). In this report we have analyzed the HLA-A2-restricted responses against eight epitopes derived from the small HBV envelope protein.
Using peptide immunization, we have first shown that eight immunodominant epitopes derived from the HBV envelope protein are presented by the HLA-A2 chimeric molecule and that they stimulate CTL induction in HHD mice. These results indicate that the epitopes defined in the HLA-A2 context in humans are also recognized by mouse CD8+ T cells in HHD mice, and that the HHD T cell repertoire is wide enough to recognize these eight HBV-derived epitopes. Using DNA-based immunization, CTL against all epitopes carried by the encoded proteins were also induced, albeit with differing frequencies. We further found that a multispecific cytotoxic response can be simultaneously induced in a single animal, and that the response to superdominant epitopes (40) does not dampen the response to less dominant ones. In our study superdominant epitopes are defined by the detection of highly frequent specific cytotoxic CD8+ T cells in all immunized mice. On the other hand, responses specific for less dominant epitopes were sporadic, and specific CD8+ T cells were detected with lower frequencies. This could be related to the fact that the abundance of a given clone in a naive repertoire varies from mouse to mouse. In certain animals, especially for weak epitopes, such a clone may be under the threshold required to encounter its cognate Ag and to be activated (41). Interestingly, responses to subdominant epitopes can coexist with responses against superdominant epitopes. This could have important implications for the generation or the broadening of immune responses and for counteracting CTL escape mutations. This is in accordance with what was observed in acutely infected patients, for which CD8+ T cell responses are strong, polyclonal, and specific for several epitopes derived from a single protein. It was shown that CD8+ T cells specific for four different HBV envelope epitopes could coexist in a given patient (24).
It was previously shown that the peptide hierarchy in T cell responses does not strictly correlate with binding affinity to the restriction element (42). Similarly, in our DNA-based immunization study, the T cell peptide hierarchy did not correlate with the affinity of peptides for the HLA-A2 class I molecule, suggesting that competition for peptide fixation is not a major factor affecting immunodominance. DNA immunization requires protein processing and peptide transport by TAP molecules to achieve peptide presentation and CTL induction. Thus, after genetic immunization the weaker responses observed against some epitopes previously described in humans could result from a defect in processing or transport of the peptides in mice. It has been shown that mouse TAP transporters are less permissive than human TAP transporters (43). In addition, we cannot exclude a competition in APC recognition between CD8+ T cells specific for the superdominant epitopes and T cells specific for other epitopes (44). Nevertheless, after two rounds of in vitro stimulation the responses specific for the weaker epitopes were confirmed by a higher number of mice recognizing these epitopes and by an increase in T cell cytotoxic activity. This confirms the relevance of the low responses against weak epitopes that could also be due to the limited number of CD8+ T cells in these Tg mice that never exceeded 5%. Moreover, in humans only CD8+ T cells specific for dominant epitopes (HBs335–343 or HBc18–27) have been detected ex vivo by tetramer staining without amplification (45). In contrast, detection of cytotoxic activity specific for less dominant epitopes required in vitro stimulation of T cells during at least 2 wk and in the presence of cytokines (24).
CTLs specific for the two superdominant epitopes (HBs183–191 and HBs348–357) were very frequent in DNA-immunized HHD mice. During acute HBV infection in humans the cytotoxic response is strong, polyclonal, and multiepitopic and is associated with viral clearance (46, 47). In self-limited acute infection several epitopes, notably HBc18–27, HBs183–191, and HBs335–343, are recognized by the majority of infected patients (4, 45). The frequency of HBV-specific CD8+ T cells detected by tetramer staining in acutely infected patients varied from 0.4 to 1.2/1000 CD8+ T cells depending on the epitope and the patient (45). In addition, in uninfected but intradermally HBsAg-vaccinated individuals, CD8+ T cell responses were measured by ex vivo ELISPOT assay, with frequencies for HLA-A2-restricted envelope epitopes ranging from 0.3 to 1.2/1000 CD8+ T cells (48). The epitope HBs183–191, shown here in HHD DNA-immunized mice to be superdominant, belongs to the group of peptides most frequently recognized by CD8+ T cells from acutely infected patients, and its frequency in mice (1/1000 CD8+ T cells) is comparable to that observed in acutely infected patients. Regarding the epitope HBs335–343 frequently recognized in humans, DNA-based immunization did not induce a strong CD8+ T cell response against this epitope, although specific T cells were present in HHD mice, as demonstrated by peptide injection. The weak response to HBs335–343 was also observed in another model of HLA-A2.1 mice using polyepitopic DNA constructs (49), suggesting a defect in Ag processing or transport. It has been shown that the proteasome may in some cases destroy the epitope by cleavage (50) and that TAP molecules do not transport all peptide precursors into the endoplasmic reticulum (51). Also, we cannot exclude that the cytokine environment could differ after virus infection or genetic immunization. It has been shown that in an inflammatory condition the constitutive proteasome is modified into immunoproteasome and that the epitope processing could be affected by either favoring or dampening epitope production (52). In addition, an alternative processing pathway is available for specific CTL induction by HBsAg, since exogenous envelope Ag can also enter the class I processing pathway and induce class I-restricted CTL (53, 54). It was also shown that the alternative exogenous or the classical endogenous pathway may generate different peptides in mice (54). The processing of HBsAg secreted following natural infection or produced after DNA-based immunization could thus result in slightly different sets of epitopes.
When stimulated in vitro, the CTL induced in HHD mice produced IFN-
after recognition of endogenously processed peptides. Experiments in
HBV transgenic mice have provided evidence for the roles of IFN- and
TNF- in the antiviral response to HBV (5, 17). In
humans a predominance of Th0 cells was detected in the liver, thus
favoring the persistence of the virus (55, 56). In
contrast to what was observed during chronic hepatitis, a
strong IFN- production by Th1 cells in the peripheral blood was
detected following antigenic stimulation of PBMC from acutely infected
patients (57). Thus, it is tempting to speculate that
IFN--secreting T cells induced after DNA-based immunization could
facilitate eradication of HBV infection in the liver.
Our studies show that DNA-based immunization of HHD mice can effectively induce CTL responses comparable to those against HLA-A2-restricted epitopes observed in HBV-infected patients. This suggests that the pathways of Ag processing and presentation for MHC class I-restricted CTL recognition of viral proteins expressed after DNA immunization mimic those previously described for viral infection, and that DNA-induced CTL could have the same immune potential as those developing during natural infection in human patients.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Marie-Louise Michel, Unité de Recombinaison et Expression Génétique, Institut National de la Santé et de la Recherche Médicale, Unité 163, Institut Pasteur, 28 rue du Docteur Roux, 75724 Paris Cedex 15, France.
3 Abbreviations used in this paper: HBV, hepatitis B virus; HBsAg, hepatitis B surface Ag; HBcAg, hepatitis B core antigen; ß2m, ß2-microglobulin; CM, culture medium; ELISPOT, enzyme-linked immunospot; MOI, multiplicity of infection; rVV, recombinant vaccinia virus; SFC, spot-forming cells; HHD, Human Human Db.
Received for publication March 17, 2000. Accepted for publication July 27, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
-secreting T cells after DNA-based immunization. J. Immunol. 161:5564.This article has been cited by other articles:
|
|
 |
|
  L. T. Mars, J. Bauer, D. A. Gross, F. Bucciarelli, H. Firat, D. Hudrisier, F. Lemonnier, K. Kosmatopoulos, and R. S. Liblau CD8 T Cell Responses to Myelin Oligodendrocyte Glycoprotein-Derived Peptides in Humanized HLA-A*0201-Transgenic Mice J. Immunol., October 15, 2007; 179(8): 5090 - 5098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Blancou, R. Mallone, E. Martinuzzi, S. Severe, S. Pogu, G. Novelli, G. Bruno, B. Charbonnel, M. Dolz, L. Chaillous, et al. Immunization of HLA Class I Transgenic Mice Identifies Autoantigenic Epitopes Eliciting Dominant Responses in Type 1 Diabetes Patients J. Immunol., June 1, 2007; 178(11): 7458 - 7466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mancini-Bourgine, F. Bayard, P. Soussan, Q. Deng, Y.-C. Lone, D. Kremsdorf, and M.-L. Michel Hepatitis B Virus Splice-Generated Protein Induces T-Cell Responses in HLA-Transgenic Mice and Hepatitis B Virus-Infected Patients J. Virol., May 15, 2007; 81(10): 4963 - 4972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Robek, M. L. Garcia, B. S. Boyd, and F. V. Chisari Role of Immunoproteasome Catalytic Subunits in the Immune Response to Hepatitis B Virus J. Virol., January 15, 2007; 81(2): 483 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hu, X. Peng, T. D. Schell, L. R. Budgeon, N. M. Cladel, and N. D. Christensen An HLA-A2.1-Transgenic Rabbit Model to Study Immunity to Papillomavirus Infection J. Immunol., December 1, 2006; 177(11): 8037 - 8045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Adotevi, K. Mollier, C. Neuveut, S. Cardinaud, E. Boulanger, B. Mignen, W.-H. Fridman, M. Zanetti, P. Charneau, E. Tartour, et al. Immunogenic HLA-B*0702-Restricted Epitopes Derived from Human Telomerase Reverse Transcriptase That Elicit Antitumor Cytotoxic T-Cell Responses. Clin. Cancer Res., May 15, 2006; 12(10): 3158 - 3167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-P. Woo, T. Doan, K. A. Herd, H.-J. Netter, and R. W. Tindle Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J. Virol., April 1, 2006; 80(8): 3975 - 3984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Takaki, M. P. Marron, C. E. Mathews, S. T. Guttmann, R. Bottino, M. Trucco, T. P. DiLorenzo, and D. V. Serreze HLA-A*0201-Restricted T Cells from Humanized NOD Mice Recognize Autoantigens of Potential Clinical Relevance to Type 1 Diabetes. J. Immunol., March 1, 2006; 176(5): 3257 - 3265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schirmbeck, P. Riedl, N. Fissolo, F. A. Lemonnier, A. Bertoletti, and J. Reimann Translation from Cryptic Reading Frames of DNA Vaccines Generates an Extended Repertoire of Immunogenic, MHC Class I-Restricted Epitopes J. Immunol., April 15, 2005; 174(8): 4647 - 4656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Loirat, M. Mancini-Bourgine, J.-P. Abastado, and M.-L. Michel HBsAg/HLA-A2 transgenic mice: a model for T cell tolerance to hepatitis B surface antigen in chronic hepatitis B virus infection Int. Immunol., October 1, 2003; 15(10): 1125 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Chun, J. Lee, H. S. Cheong, and K.-Y. Lee Tumor Eradication by Hepatitis B Virus X Antigen-Specific CD8+ T Cells in Xenografted Nude Mice J. Immunol., February 1, 2003; 170(3): 1183 - 1190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Marsac, D. Loirat, C. Petit, O. Schwartz, and M.-L. Michel Enhanced Presentation of Major Histocompatibility Complex Class I-Restricted Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Specific Epitopes after DNA Immunization with Vectors Coding for Vesicular Stomatitis Virus Glycoprotein- Pseudotyped HIV-1 Gag Particles J. Virol., June 27, 2002; 76(15): 7544 - 7553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Palmowski, E. M.-L. Choi, I. F. Hermans, S. C. Gilbert, J.-L. Chen, U. Gileadi, M. Salio, A. Van Pel, S. Man, E. Bonin, et al. Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols J. Immunol., May 1, 2002; 168(9): 4391 - 4398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Brinster, M. Chen, D. Boucreux, G. Paranhos-Baccala, P. Liljestrom, F. Lemmonier, and G. Inchauspe Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles J. Gen. Virol., February 1, 2002; 83(2): 369 - 381. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
10%
at an E:T cell ratio of 100/1. Panels represent specific lysis for an
E:T cell ratio of 100/1 in five to nine independently tested mice
immunized with the same HBsAg peptide. The positions of the peptides on
the HBV envelope protein are indicated under each panel. The numbers of
responder vs tested animals are indicated in bold above the columns.
Columns represent the mean ± SEM of three determinations.
) as APC.
Cytotoxic activity was evaluated on HeLa-HHD (left) and
on P815/A2 (right) target cells expressing the chimeric
(HHD) or the wild-type HLA-A*201 molecules, respectively. Targets were
peptide loaded (continuous lines) or unloaded (dotted lines) cells.
Three determinations of cytotoxic activity were performed, and SEMs are
given. Results are shown for one representative mouse.
) spleen populations 3 wk after injection of pCMV-S2.S plasmid.
Splenocytes were infected with recombinant vaccinia virus (rVV-S1.S2.S)
encoding the three HBV envelope proteins (A) or cultured
in the presence of pre-S2-derived T helper peptide (B).
Background levels were measured, respectively, after infection of
splenocytes with wild-type vaccinia virus or in wells containing
splenocytes in medium only and were subtracted from the specific number
of SFC. Results are given for the mean ± SEM of three
individual mice.